nivolumab,tafasitamab,magrolimab
morphosys,incyte,bms,Gilead
['lymphoma', 'dlbcl', 'lymsm']
congress #eha2023 | talks through immunotherapy treatment paradigm in relapsed/refractory dlbcl. he discusses monotherapy &amp; combination/sequential approaches with mabs, abs drug conjugate, car-t cells &amp; bispecific abs.
#lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm